Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma: a therapeutic enigma

B Hoogstraten

    American Journal of Clinical Oncology
    |February 1, 1982
    PubMed
    Summary

    Despite a distinct tumor marker and numerous chemotherapy drugs, multiple myeloma outcomes have seen minimal improvement over the past two decades. This persistent challenge highlights the need for novel therapeutic strategies in multiple myeloma treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial.

    American journal of clinical oncology·1992
    Same author

    Continuous infusion of interleukin-2 and cyclophosphamide as treatment of advanced cancers: a National Biotherapy Study Group Trial.

    Molecular biotherapy·1991
    Same author

    Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1989
    Same author

    Malignant effusions and their management.

    Seminars in oncology nursing·1985
    Same author

    Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.

    Investigational new drugs·1985
    Same author

    Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study.

    Cancer·1984

    Area of Science:

    • Hematology
    • Oncology
    • Cancer Research

    Background:

    • Multiple myeloma is a malignancy characterized by a unique tumor marker, the myeloma protein.
    • Early chemotherapy regimens in the 1960s, including melphalan and cyclophosphamide, showed initial promise.
    • Despite advancements, significant progress in improving patient outcomes has been limited in recent decades.

    Purpose of the Study:

    • To review the historical treatment landscape of multiple myeloma.
    • To highlight the persistent challenges in improving patient outcomes despite available therapies.
    • To underscore the need for further research and novel therapeutic approaches.

    Main Methods:

    • Review of historical data on multiple myeloma treatment efficacy.
    • Analysis of chemotherapy drug development and combination therapy trials.
    • Evaluation of trends in patient outcomes over the last two decades.

    Main Results:

    • Multiple myeloma possesses a distinct tumor marker, enabling disease monitoring.
    • Early chemotherapy demonstrated effectiveness, but subsequent advancements have yielded limited improvements in outcomes.
    • Despite extensive research and drug development, patient prognosis has seen little change in the last 20 years.

    Conclusions:

    • The lack of significant progress in multiple myeloma outcomes is an ongoing enigma.
    • Novel therapeutic strategies are crucial to overcome treatment resistance and improve patient survival.
    • Further investigation into the biology and treatment of multiple myeloma is warranted.

    Related Experiment Videos